A longitudinal assessment of patient-reported outcomes demonstrated that pexidartinib (Turalio) continues to offer clinically meaningful symptom relief with extended use in patients with tenosynovial ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...